🇺🇸 FDA
Pipeline program

alpha receptor antagonist

2024HS197

Phase 1 small_molecule active

Quick answer

alpha receptor antagonist for Prostatic Hypertrophy, Benign is a Phase 1 program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Prostatic Hypertrophy, Benign
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials